ReviewViruses2021
SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants.
Review in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Catalase: A Potential Pharmacologic Target for Hydrogen Peroxide in the Treatment of COVID-19.Current topics in medicinal chemistry · 2024Pooled it
- Presepsin levels and COVID-19 severity: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- A comparative study on proinflammatory cytokines interleukin-17A and interleukin-17F expressions in whole blood of patients with COVID-19.Iranian journal of microbiology · 2025Article
- Digital Immunoassay for Rapid Detection of SARS-CoV-2 exposure in a Broad Spectrum of Animals.IEEE sensors journal · 2025Article
- Serological surveillance for SARS-CoV-2 antibodies among students, faculty and staff within a large university system during the pandemic.World journal of virology · 2025Article
- Assessing COVID-19 Vaccine Effectiveness and Risk Factors for Severe Outcomes through Machine Learning Techniques: A Real-World Data Study in Andalusia, Spain.Journal of epidemiology and global health · 2024Article
- A Regional-Scale Assessment-Based SARS-CoV-2 Variants Control Modeling with Implications for Infection Risk Characterization.Infection and drug resistance · 2024Article
- The trend of phylogenetic and epitope variations of SARS-CoV-2 Omicron sub-lineages in Iran.Frontiers in microbiology · 2024Article
- A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.Current topics in medicinal chemistry · 2024Review
- Exploring the medicinal potential of Dark Chemical Matters (DCM) to design promising inhibitors for PLpro of SARS-CoV-2 using molecular screening and simulation approaches.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Special Issue: Advances in SARS-CoV-2 Infection.Microorganisms · 2023Article
- [Adjustment of poor prognostic factors in patients with COVID-19 to the current scenario].Anales del sistema sanitario de Navarra · 2023Article
- [Adjustment of poor prognostic factors in patients with COVID-19 to the current scenario].Anales del sistema sanitario de Navarra · 2023Article
- The Breadth of Bacteriophages Contributing to the Development of the Phage-Based Vaccines for COVID-19: An Ideal Platform to Design the Multiplex Vaccine.International journal of molecular sciences · 2023Review
- Computational Modeling and Evaluation of Potential mRNA and Peptide-Based Vaccine against Marburg Virus (MARV) to Provide Immune Protection against Hemorrhagic Fever.BioMed research international · 2023Article
- Attitudes towards receiving COVID-19 vaccine and its associated factors among Southwest Ethiopian adults, 2021.PloS one · 2023Article
- Article
- Article
- SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker of Iraq: A case report.Human vaccines & immunotherapeutics · 2022Article
- HIV and SARS-CoV-2 Pathogenesis and Vaccine Development.Viruses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly discovered coronavirus responsible for the coronavirus disease 2019 (COVID-19) pandemic. COVID-19 has rapidly become a public health emergency of international concern. Although remarkable scientific achievements have been reached since the beginning of the pandemic, the knowledge behind this novel coronavirus, in terms of molecular and pathogenic characteristics and zoonotic potential, is still relatively limited. Today, there is a vaccine, or rather several vaccines, which, for the first time in the history of highly contagious infectious diseases that have plagued mankind, has been manufactured in just one year. Currently, four vaccines are licensed by regulatory agencies, and they use RNA or viral vector technologies. The positive effects of the vaccination campaign are being felt in many parts of the world, but the disappearance of this new infection is still far from being a reality, as it is also threatened by the presence of novel SARS-CoV-2 variants that could undermine the effectiveness of the vaccine, hampering the immunization control efforts. Indeed, the current findings indicate that SARS-CoV-2 is adapting to transmission in humans more efficiently, while further divergence from the initial archetype should be considered. In this review, we aimed to provide a collection of the current knowledge regarding the molecular, phylogenetic, and pathogenetic insights into SARS-CoV-2. The most recent findings obtained with respect to the impact of novel emerging SARS-CoV-2 variants as well as the development and implementation of vaccines are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.